Synthesis and bioevaluation of novel benzodipyranone derivatives as P-glycoprotein inhibitors for multidrug resistance reversal agents

European Journal of Medicinal Chemistry

Volumn 118, Issue , 2016, Pages 219-229

  Chen, Chien Yu ^a   Liu, Nai Yu ^a   Lin, Hui Chang ^a   Lee, Chih Yu ^a   Hung, Chin Chuan ^a   Chang, Chih Shiang ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Benzodipyranone; Multidrug resistance; P glycoprotein; Reversal agent

Indexed keywords

3,9 BIS(2 CHLORO 6 FLUOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(2 CHLOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(2 FLUOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(3 CHLOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(3 FLUOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(3,4 DICHLOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(3,4 DIMETHOXYPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(4 CHLOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(4 FLUOROPHENYL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 3,9 BIS(BENZO[D][1,3]DIOXOL 5 YL) 5 HYDROXYPYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(2 METHOXYPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(2 NITROPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(3 HYDROXYPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(3 METHOXYPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(3,4,5 TRIMETHOXYPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(4 METHOXYPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS(4 NITROPHENYL)PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS[2 (TRIFLUOROMETHYL)PHENYL]PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS[3 (TRIFLUOROMETHYL)PHENYL]PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 BIS[4 (TRIFLUOROMETHYL)PHENYL]PYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 DI 2 TOLYLPYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 DI 3 TOLYLPYRANO[2,3 F]CHROMENE 4,10 DIONE; 5 HYDROXY 3,9 DI 4 TOLYLPYRANO[2,3 F]CHROMENE 4,10 DIONE; BENZODIPYRANONE DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; PACLITAXEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PYRAN DERIVATIVE;

ARTICLE; CALCEIN-AM ASSAY; CANCER CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN CONFORMATION; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROTEIN CONFORMATION; PYRANS; RNA, MESSENGER;

EID: 84964781225     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.03.070     Document Type: Article

References (26)

1. C. Ramalhete, J. Molnar, S. Mulhovo, V.E. Rosario, and M.J. Ferreira New potent P-glycoprotein modulators with the cucurbitane scaffold and their synergistic interaction with doxorubicin on resistant cancer cells Bioorg. Med. Chem. 17 2009 6942 6951
2. L. Jiao, Q. Qiu, B. Liu, T. Zhao, W. Huang, and H. Qian Design, synthesis and evaluation of novel triazole core based P-glycoprotein-mediated multidrug resistance reversal agents Bioorg. Med. Chem. 22 2014 6857 6866
3. G.A. Sawada, T.J. Raub, J. William Higgins, N.K. Brennan, T.M. Moore, G. Tombline, and M.R. Detty Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells Bioorg. Med. Chem. 16 2008 9745 9756
4. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
5. D.W. Shen, S. Goldenberg, I. Pastan, and M.M. Gottesman Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake J. Cell Physiol. 183 2000 108 116
6. C. Xu, C.Y. Li, and A.N. Kong Induction of phase I, II and III drug metabolism/transport by xenobiotics Arch. Pharm. Res. 28 2005 249 268
7. S.W. Lowe, H.E. Ruley, T. Jacks, and D.E. Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
8. E. Capparelli, L. Zinzi, M. Cantore, M. Contino, M.G. Perrone, G. Luurtsema, F. Berardi, R. Perrone, and N.A. Colabufo SAR studies on tetrahydroisoquinoline derivatives: the role of flexibility and bioisosterism to raise potency and selectivity toward P-glycoprotein J. Med. Chem. 57 2014 9983 9994
9. Z. Wang, I.L. Wong, F.X. Li, C. Yang, Z. Liu, T. Jiang, T.F. Jiang, L.M. Chow, and S.B. Wan Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors Bioorg. Med. Chem. 23 2015 5566 5573
10. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1981 1967 1972
11. W. Van de Vrie, E.E. Gheuens, N.M. Durante, E.A. De Bruijn, R.L. Marquet, A.T. Van Oosterom, and A.M. Eggermont In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour J. Cancer Res. Clin. Oncol. 119 1993 609 614
12. T. Tsuruo, H. Iida, Y. Kitatani, K. Yokota, S. Tsukagoshi, and Y. Sakurai Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells Cancer Res. 44 1984 4303 4307
13. V. Fischer, A. Rodriguez-Gascon, F. Heitz, R. Tynes, C. Hauck, D. Cohen, and A.E. Vickers The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite Drug Metab. Dispos. 26 1998 802 811
14. E. Warner, D. Hedley, I. Andrulis, R. Myers, M. Trudeau, D. Warr, K.I. Pritchard, M. Blackstein, P.E. Goss, E. Franssen, K. Roche, S. Knight, S. Webster, R.A. Fraser, S. Oldfield, W. Hill, and R. Kates Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen Clin. Cancer Res. 4 1998 1451 1457
15. H. Thomas, and H.M. Coley Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein Cancer control J. Moffitt Cancer Cent. 10 2003 159 165
16. L. Pusztai, P. Wagner, N. Ibrahim, E. Rivera, R. Theriault, D. Booser, F.W. Symmans, F. Wong, G. Blumenschein, D.R. Fleming, R. Rouzier, G. Boniface, and G.N. Hortobagyi Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma Cancer 104 2005 682 691
17. J.S. Lagas, R.A. van Waterschoot, V.A. van Tilburg, M.J. Hillebrand, N. Lankheet, H. Rosing, J.H. Beijnen, and A.H. Schinkel Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment Clin. Cancer Res. 15 2009 2344 2351
18. I.E. Kuppens, E.O. Witteveen, R.C. Jewell, S.A. Radema, E.M. Paul, S.G. Mangum, J.H. Beijnen, E.E. Voest, and J.H. Schellens A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients Clin. Cancer Res. 13 2007 3276 3285
19. C.A. McDevitt, and R. Callaghan How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther. 113 2007 429 441
20. M.L. Amin P-glycoprotein inhibition for optimal drug delivery Drug Target Insights 7 2013 27 34
21. N.U.-D. Khan, N. Parveen, M.P. Singh, R. Singh, B. Achari, P.P.G. Dastidar, and P.K. Dutta Two isomeric benzodipyranone derivatives from Calophyllum inophyllum Phytochemistry 42 1996 1181 1183
22. J.R. Bantick, H. Cairns, A. Chambers, R. Hazard, J. King, and T.B. Lee Benzodipyran derivatives with antiallergic activity J. Med. Chem. 19 1976 817 821
23. C.C. Hung, M.H. Chiou, Y.N. Teng, Y.W. Hsieh, C.L. Huang, and H.Y. Lane Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone PloS one 8 2013 e59419
24. C.C. Hung, and H.H. Liou YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway Investig. New Drugs 29 2011 1337 1346
25. K. Nakagawa-Goto, A. Oda, E. Hamel, E. Ohkoshi, K.H. Lee, and M. Goto Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring J. Med. Chem. 58 2015 2378 2389
26. P. Szewczyk, H. Tao, A.P. McGrath, M. Villaluz, S.D. Rees, S.C. Lee, R. Doshi, I.L. Urbatsch, Q. Zhang, and G. Chang Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein Acta Cryst. D. 71 2015 732 741